Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (Cipla Ltd.), 贝伐珠单抗生物类似药(Cipla Ltd.) + [2] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (02 Nov 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Renal Cell Carcinoma | AU | 02 Nov 2021 | |
Breast cancer recurrent | AU | 02 Nov 2021 | |
High grade glioma | AU | 02 Nov 2021 | |
Metastatic breast cancer | AU | 02 Nov 2021 | |
Metastatic Cervical Carcinoma | AU | 02 Nov 2021 | |
Metastatic Colorectal Carcinoma | AU | 02 Nov 2021 | |
Metastatic Renal Cell Carcinoma | AU | 02 Nov 2021 | |
Non-squamous non-small cell lung cancer | AU | 02 Nov 2021 | |
Platinum-Resistant Epithelial Ovarian Carcinoma | AU | 02 Nov 2021 | |
Platinum-Resistant Fallopian Tube Carcinoma | AU | 02 Nov 2021 | |
Platinum-Resistant Primary Peritoneal Carcinoma | AU | 02 Nov 2021 | |
Recurrent Cervical Cancer | AU | 02 Nov 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | NDA/BLA | - | 01 Dec 2016 | |
Neoplasms | NDA/BLA | NZ | 01 Jun 2016 |